

Annalisa Berzigotti

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9365927/publications.pdf>

Version: 2024-02-01

258
papers

16,114
citations

17440

63
h-index

18647

119
g-index

268
all docs

268
docs citations

268
times ranked

10700
citing authors

#	ARTICLE	IF	CITATIONS
1	Two-dimensional shear wave elastography predicts survival in advanced chronic liver disease. <i>Gut</i> , 2022, 71, 402-414.	12.1	39
2	FIB-4 Improves LSM-Based Prediction of Complications in Overweight or Obese Patients With Compensated Advanced Chronic Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 2396-2398.e3.	4.4	3
3	Decompensation in Advanced Nonalcoholic Fatty Liver Disease May Occur at Lower Hepatic Venous Pressure Gradient Levels Than in Patients With Viral Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 2276-2286.e6.	4.4	42
4	Validation of a standardized CT protocol for the evaluation of varices and porto-systemic shunts in cirrhotic patients. <i>European Journal of Radiology</i> , 2022, 147, 110010.	2.6	13
5	Reply to: Correspondence on "EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis" 2021 update. <i>Journal of Hepatology</i> , 2022, 76, 251-252.	3.7	1
6	Development of and Gathering Validity Evidence for a Theoretical Test in Contrast-Enhanced Ultrasound. <i>Ultrasound in Medicine and Biology</i> , 2022, 48, 248-256.	1.5	1
7	Inflammatory activity affects the accuracy of liver stiffness measurement by transient elastography but not by two-dimensional shear wave elastography in non-alcoholic fatty liver disease. <i>Liver International</i> , 2022, 42, 102-111.	3.9	13
8	Liver-related and extrahepatic events in patients with non-alcoholic fatty liver disease: a retrospective competing risks analysis. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 604-615.	3.7	18
9	Resolution of Precapillary Pulmonary Hypertension After Liver Transplantation for Hereditary Hemorrhagic Telangiectasia: Systematic Review and Case Report. <i>Transplantation Proceedings</i> , 2022, 54, 135-143.	0.6	3
10	Current treatment options of refractory ascites in liver cirrhosis " A systematic review and meta-analysis. <i>Digestive and Liver Disease</i> , 2022, 54, 1007-1014.	0.9	12
11	Current considerations for clinical management and care of non-alcoholic fatty liver disease: Insights from the 1st International Workshop of the Canadian NASH Network (CanNASH). <i>Canadian Liver Journal</i> , 2022, 5, 61-90.	0.9	7
12	Screening for hepatocellular carcinoma among adults with HIV/HBV co-infection in Zambia: a pilot study. <i>International Journal of Infectious Diseases</i> , 2022, 116, 391-396.	3.3	4
13	Baveno VII "Renewing consensus in portal hypertension. <i>Journal of Hepatology</i> , 2022, 76, 959-974.	3.7	890
14	A cholestatic pattern predicts major liver-related outcomes in patients with non-alcoholic fatty liver disease. <i>Liver International</i> , 2022, 42, 1037-1048.	3.9	4
15	T1 reduction rate with Gd-EOB-DTPA determines liver function on both 1.5T and 3T MRI. <i>Scientific Reports</i> , 2022, 12, 4716.	3.3	5
16	Which preoperative assessment modalities best identify patients who are suitable for enhanced recovery after liver transplantation? A systematic review of the literature and expert panel recommendations. <i>Clinical Transplantation</i> , 2022, 36, e14644.	1.6	11
17	Comparison of screening strategies with two new tests to score and diagnose varices needing treatment. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2022, 46, 101925.	1.5	2
18	Porto-sinusoidal vascular disorder. <i>Journal of Hepatology</i> , 2022, 77, 1124-1135.	3.7	41

#	ARTICLE	IF	CITATIONS
19	Including Ratio of Platelets to Liver Stiffness Improves Accuracy of Screening for Esophageal Varices That Require Treatment. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 777-787.e17.	4.4	19
20	Monitoring Occurrence of Liver-Related Events and Survival by Transient Elastography in Patients With Nonalcoholic Fatty Liver Disease and Compensated Advanced Chronic Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 806-815.e5.	4.4	90
21	Liver segmental volume and attenuation ratio (LSVAR) on portal venous CT scans improves the detection of clinically significant liver fibrosis compared to liver segmental volume ratio (LSVR). <i>Abdominal Radiology</i> , 2021, 46, 1912-1921.	2.1	4
22	T1 mapping of the liver and the spleen in patients with liver fibrosisâ€”does normalization to the blood pool increase the predictive value?. <i>European Radiology</i> , 2021, 31, 4308-4318.	4.5	10
23	Royal Free Hospitalâ€”Estimated glomerular filtration rate for prognostic stratification of first acute kidney injury in cirrhosis. <i>Liver International</i> , 2021, 41, 819-827.	3.9	2
24	Applicability and Results of Liver Stiffness Measurement and Controlled Attenuation Parameter Using XL Probe for Metabolic-Associated Fatty Liver Disease in Candidates to Bariatric Surgery. A Single-Center Observational Study. <i>Obesity Surgery</i> , 2021, 31, 702-711.	2.1	7
25	Malnutrition and Alcohol in Patients Presenting with Severe Complications of Cirrhosis After Laparoscopic Bariatric Surgery. <i>Obesity Surgery</i> , 2021, 31, 2817-2822.	2.1	8
26	Dietary Interventions in Liver Diseases: Focus on MAFLD and Cirrhosis. <i>Current Hepatology Reports</i> , 2021, 20, 61-76.	0.9	2
27	Noninvasive Detection of Clinically Significant Portal Hypertension in Compensated Advanced Chronic Liver Disease. <i>Clinics in Liver Disease</i> , 2021, 25, 253-289.	2.1	26
28	Predicting portal thrombosis in cirrhosis: A prospective study of clinical, ultrasonographic and hemostatic factors. <i>Journal of Hepatology</i> , 2021, 75, 1367-1376.	3.7	73
29	Risks and Rewards of Bariatric Surgery in Advanced Chronic Liver Diseases. <i>Seminars in Liver Disease</i> , 2021, 41, 448-460.	3.6	9
30	Acute splanchnic vein thrombosis in patients with COVID-19: A systematic review. <i>Digestive and Liver Disease</i> , 2021, 53, 937-949.	0.9	16
31	EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis â€” 2021 update. <i>Journal of Hepatology</i> , 2021, 75, 659-689.	3.7	676
32	Quantification of Liver Fat Content with Ultrasound: A WFUMB Position Paper. <i>Ultrasound in Medicine and Biology</i> , 2021, 47, 2803-2820.	1.5	63
33	Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: A systematic review and meta-analysis. <i>Journal of Hepatology</i> , 2021, 75, 770-785.	3.7	149
34	OC-06A cholestatic pattern predicts liver-related events in patients with nonalcoholic fatty liver disease. <i>Digestive and Liver Disease</i> , 2021, 53, S3-S4.	0.9	0
35	Resistance to thrombomodulin correlates with liver stiffness in chronic liver disease a prospective single-center cohort study. <i>Thrombosis Research</i> , 2021, 207, 40-49.	1.7	2
36	Noninvasive assessment of clinically significant portal hypertension using $\hat{T}1$ of the liver and spleen and ECV of the spleen on routine Gd-EOB-DTPA liver MRI. <i>European Journal of Radiology</i> , 2021, 144, 109958.	2.6	4

#	ARTICLE	IF	CITATIONS
37	Assessing Disease Severity and Prognosis. , 2021, , 173-190.		0
38	Noninvasive Assessment of <i>Schistosoma</i>-Related Periportal Fibrosis. Journal of Ultrasound in Medicine, 2021, 40, 2273-2287.	1.7	4
39	Noninvasive Diagnosis of Portal Hypertension in Patients With Compensated Advanced Chronic Liver Disease. American Journal of Gastroenterology, 2021, 116, 723-732.	0.4	105
40	Management of Lifestyle Factors in Individuals with Cirrhosis: A Pragmatic Review. Seminars in Liver Disease, 2020, 40, 020-028.	3.6	11
41	Randomized placebo-controlled trial of emricasan for non-alcoholic steatohepatitis-related cirrhosis with severe portal hypertension. Journal of Hepatology, 2020, 72, 885-895.	3.7	107
42	Controlled attenuation parameter reflects steatosis in compensated advanced chronic liver disease. Liver International, 2020, 40, 1151-1158.	3.9	17
43	Nuclear deformation mediates liver cell mechanosensing in cirrhosis. JHEP Reports, 2020, 2, 100145.	4.9	35
44	Guidelines and Good Clinical Practice Recommendations for Contrast Enhanced Ultrasound (CEUS) in the Liver â€“ Update 2020 â€“ WFUMB in Cooperation with EFSUMB, AFSUMB, AIUM, and FLAUS. Ultraschall in Der Medizin, 2020, 41, 562-585.	1.5	130
45	Guidelines and Good Clinical Practice Recommendations for Contrast-Enhanced Ultrasound (CEUS) in the Liverâ€“Update 2020 WFUMB in Cooperation with EFSUMB, AFSUMB, AIUM, and FLAUS. Ultrasound in Medicine and Biology, 2020, 46, 2579-2604.	1.5	210
46	Effect of poorly absorbable antibiotics on hepatic venous pressure gradient in cirrhosis: A systematic review and meta-analysis. Digestive and Liver Disease, 2020, 52, 958-965.	0.9	11
47	A hypercoagulable state does not play a major role in the development of portal vein thrombosis in patients with cirrhosis. Journal of Hepatology, 2020, 73, S711-S712.	3.7	2
48	The prevalence of esophageal varices needing treatment depends on gender, etiology and BMI. Journal of Hepatology, 2020, 73, S751-S752.	3.7	1
49	Effect of rifaximin or norfloxacin on hepatic venous pressure gradient in patients with cirrhosis: a systematic review and meta-analysis. Journal of Hepatology, 2020, 73, S772-S773.	3.7	0
50	Bidimensional shear wave elastography of the rectus femoris muscle in patients with cirrhosis. Journal of Hepatology, 2020, 73, S696.	3.7	1
51	2D shear wave liver elastography by Aixplorer to detect portal hypertension in cirrhosis: An individual patient data metaâ€“analysis. Liver International, 2020, 40, 1435-1446.	3.9	35
52	Transjugular intrahepatic portosystemic shunt and alfapumpÂ® system for refractory ascites in liver cirrhosis: Outcomes and complications. United European Gastroenterology Journal, 2020, 8, 961-969.	3.8	8
53	The prevalence of esophageal varices needing treatment depends on gender, etiology and BMI. Digestive and Liver Disease, 2020, 52, e60.	0.9	0
54	Sarcopenia correlates with mortality in cirrhotic patients who undergo transjugular intrahepatic portosystemic shunt creation for refractory ascites. Digestive and Liver Disease, 2020, 52, e62.	0.9	1

#	ARTICLE	IF	CITATIONS
55	A Prognostic Strategy Based on Stage of Cirrhosis and HVPG to Improve Risk Stratification After Variceal Bleeding. <i>Hepatology</i> , 2020, 72, 1353-1365.	7.3	32
56	Total area of spontaneous portosystemic shunts independently predicts hepatic encephalopathy and mortality in liver cirrhosis. <i>Journal of Hepatology</i> , 2020, 72, 1140-1150.	3.7	97
57	Noninvasive Markers of Portal Hypertension Detect Decompensation in Overweight or Obese Patients With Compensated Advanced Chronic Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 3017-3025.e6.	4.4	21
58	Benefits, Open questions and Challenges of the use of Ultrasound in the COVID-19 pandemic era. The views of a panel of worldwide international experts. <i>Ultraschall in Der Medizin</i> , 2020, 41, 228-236.	1.5	46
59	Liver and Spleen Stiffness to Predict Portal Hypertension and Its Complications. , 2020, , 325-359.		0
60	Non-invasive Assessment of Non-alcoholic Fatty Liver Disease: Ultrasound and Transient Elastography. , 2020, , 115-139.		1
61	EASL Clinical Practice Guidelines on nutrition in chronic liver disease. <i>Journal of Hepatology</i> , 2019, 70, 172-193.	3.7	608
62	The prognostic role of hepatic venous pressure gradient in cirrhotic patients undergoing elective extrahepatic surgery. <i>Journal of Hepatology</i> , 2019, 71, 942-950.	3.7	61
63	Liver MRI susceptibility-weighted imaging (SWI) compared to T2* mapping in the presence of steatosis and fibrosis. <i>European Journal of Radiology</i> , 2019, 118, 66-74.	2.6	16
64	LBO-01-Multicenter, double-blind, placebo-controlled, randomized trial of emricasan in subjects with NASH cirrhosis and severe portal hypertension. <i>Journal of Hepatology</i> , 2019, 70, e127.	3.7	8
65	SAT-104-Factors associated with renal replacement therapy and mortality following first episode of acute kidney injury in inpatients with cirrhosis. <i>Journal of Hepatology</i> , 2019, 70, e674-e675.	3.7	1
66	SAT-133-2D-Shear-Wave elastography predicts survival in advanced chronic liver disease. <i>Journal of Hepatology</i> , 2019, 70, e689.	3.7	0
67	Muscle psoas indices measured by ultrasound in cirrhosis – Preliminary evaluation of sarcopenia assessment and prediction of liver decompensation and mortality. <i>Digestive and Liver Disease</i> , 2019, 51, 1502-1507.	0.9	27
68	FRI-113-Matrix stiffness modulates the phenotype of hepatic cells in cirrhosis and modifies the sinusoidal effects of statins. <i>Journal of Hepatology</i> , 2019, 70, e437.	3.7	1
69	Review article: impact of exercise on physical frailty in patients with chronic liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 988-1000.	3.7	72
70	Non-invasive Measurement of Portal Pressure. <i>Current Hepatology Reports</i> , 2019, 18, 20-27.	0.9	4
71	Adipopenia correlates with higher portal pressure in patients with cirrhosis. <i>Liver International</i> , 2019, 39, 1672-1681.	3.9	26
72	Liver MR relaxometry at 3T – segmental normal T1 and T2* values in patients without focal or diffuse liver disease and in patients with increased liver fat and elevated liver stiffness. <i>Scientific Reports</i> , 2019, 9, 8106.	3.3	25

#	ARTICLE	IF	CITATIONS
73	SAT-021-How to use platelets and liver stiffness to rule out esophageal varices needing treatment?. Journal of Hepatology, 2019, 70, e634-e635.	3.7	0
74	SAT-096-Large spontaneous portosystemic shunt (SPSS) area is associated with hepatic encephalopathy and predicts mortality in liver cirrhosis. Journal of Hepatology, 2019, 70, e670.	3.7	0
75	Letter: nonselective beta-blockers, endoscopic therapy and portal vein thrombosis in cirrhosis. Alimentary Pharmacology and Therapeutics, 2019, 49, 1370-1371.	3.7	4
76	SAT-083-Simple non-invasive surrogates of portal hypertension predict clinical decompensation in overweight/obese patients with cACLD. Journal of Hepatology, 2019, 70, e664-e665.	3.7	1
77	Patients With Signs of Advanced Liver Disease and Clinically Significant Portal Hypertension Do Not Necessarily Have Cirrhosis. Clinical Gastroenterology and Hepatology, 2019, 17, 2101-2109.e1.	4.4	24
78	Contrast-enhanced imaging in hepatic epithelioid hemangioendothelioma: retrospective study of 10 patients. Zeitschrift Fur Gastroenterologie, 2019, 57, 753-766.	0.5	17
79	Porto-sinusoidal vascular disease: proposal and description of a novel entity. The Lancet Gastroenterology and Hepatology, 2019, 4, 399-411.	8.1	149
80	Hepatic sinusoidal hemophagocytosis with and without hemophagocytic lymphohistiocytosis. PLoS ONE, 2019, 14, e0226899.	2.5	11
81	Systematic review with meta-analysis: portal vein recanalisation and transjugular intrahepatic portosystemic shunt for portal vein thrombosis. Alimentary Pharmacology and Therapeutics, 2019, 49, 20-30.	3.7	68
82	Metabolomics discloses potential biomarkers to predict the acute HVPG response to propranolol in patients with cirrhosis. Liver International, 2019, 39, 705-713.	3.9	17
83	Non-Invasive Prediction of High-Risk Varices in Patients with Primary Biliary Cholangitis and Primary Sclerosing Cholangitis. American Journal of Gastroenterology, 2019, 114, 446-452.	0.4	65
84	Liver stiffness predicts the development of portal hypertension related complications in advanced chronic liver disease. Digestive and Liver Disease, 2018, 50, 48.	0.9	0
85	Association Between Portosystemic Shunts and Increased Complications and Mortality in Patients With Cirrhosis. Gastroenterology, 2018, 154, 1694-1705.e4.	1.3	162
86	Reply. Hepatology, 2018, 67, 1645-1646.	7.3	0
87	Cuantificaci3n de la fibrosis hep3tica mediante biomarcadores de imagen. Radiologia, 2018, 60, 74-84.	0.5	8
88	Contrast enhanced ultrasound in mixed hepatocellular cholangiocarcinoma: Case series and review of the literature. Digestive and Liver Disease, 2018, 50, 401-407.	0.9	14
89	Novel ultrasound-based methods to assess liver disease: The game has just begun. Digestive and Liver Disease, 2018, 50, 107-112.	0.9	49
90	A combined model based on spleen stiffness measurement and Baveno VI criteria to rule out high-risk varices in advanced chronic liver disease. Journal of Hepatology, 2018, 69, 308-317.	3.7	142

#	ARTICLE	IF	CITATIONS
91	Editorial: use of beta-blockers and of band ligation in preventing first and recurrent variceal bleeding – a cereal life vs evidence-based decisions. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 1222-1223.	3.7	1
92	Noninvasive prediction of esophageal varices by liver stiffness measurement and platelet values in patients with liver cirrhosis due to nonalcoholic fatty liver disease: A multicenter cross-sectional study. <i>Digestive and Liver Disease</i> , 2018, 50, 3-4.	0.9	0
93	A spleen stiffness measurement-based model for the recognition of high risk varices: Baveno VI criteria and beyond. <i>Digestive and Liver Disease</i> , 2018, 50, 33-34.	0.9	0
94	Non-invasive measurement of HVPG using graph analysis based on dynamic contrast-enhanced ultrasound with ESAOTE MyLab: The CLEVER Study. <i>Digestive and Liver Disease</i> , 2018, 50, 33.	0.9	1
95	Liver elastography malignancy prediction score for noninvasive characterization of focal liver lesions. <i>Liver International</i> , 2018, 38, 1055-1063.	3.9	26
96	Imaging and minimally invasive endovascular therapy in the management of portal vein thrombosis. <i>Abdominal Radiology</i> , 2018, 43, 1931-1946.	2.1	11
97	Controlled attenuation parameter reflects intrahepatic fat content in patients with compensated advanced chronic liver disease. <i>Journal of Hepatology</i> , 2018, 68, S638.	3.7	1
98	Emerging non-invasive approaches for diagnosis and monitoring of portal hypertension. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 708-719.	8.1	100
99	Physical Activity in Liver Transplantation: A Patient's and Physicians' Experience. <i>Advances in Therapy</i> , 2018, 35, 1729-1734.	2.9	10
100	Liver Ultrasound Elastography: An Update to the World Federation for Ultrasound in Medicine and Biology Guidelines and Recommendations. <i>Ultrasound in Medicine and Biology</i> , 2018, 44, 2419-2440.	1.5	357
101	Non-invasive prediction of esophageal varices by stiffness and platelet in non-alcoholic fatty liver disease cirrhosis. <i>Journal of Hepatology</i> , 2018, 69, 878-885.	3.7	113
102	Hepatic Venous Pressure Measurement and Other Diagnostic Hepatic Hemodynamic Techniques. , 2018, , 33-48.		0
103	Noninvasive prediction of oesophageal varices by liver stiffness measurement and platelet values in patients with liver cirrhosis due to nonalcoholic fatty liver disease: A multicenter cross-sectional study. <i>Journal of Hepatology</i> , 2018, 68, S96-S97.	3.7	0
104	Subcutaneous adipose tissue is a predictor of survival in patients with hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2018, 68, S423.	3.7	0
105	Clinically significant portal hypertension in chronic liver disease: Always cirrhosis?. <i>Journal of Hepatology</i> , 2018, 68, S734.	3.7	0
106	Outcomes of intrahepatic porto-systemic shunt in the treatment of portal vein thrombosis: A systematic review and meta-analysis. <i>Journal of Hepatology</i> , 2018, 68, S734.	3.7	0
107	Ultrasonography in Liver Vascular Disease. <i>Ultraschall in Der Medizin</i> , 2018, 39, 382-405.	1.5	12
108	Non-invasive measurement of HVPG using graph analysis of dynamic contrast-enhanced ultrasound: the CLEVER study. <i>Journal of Hepatology</i> , 2018, 68, S76-S77.	3.7	5

#	ARTICLE	IF	CITATIONS
109	13C-methacetin breath test is a highly accurate non-invasive point of care test for detecting CSPH in patients with NASH. <i>Journal of Hepatology</i> , 2018, 68, S115.	3.7	1
110	CT predicts liver fibrosis: Prospective evaluation of morphology- and attenuation-based quantitative scores in routine portal venous abdominal scans. <i>PLoS ONE</i> , 2018, 13, e0199611.	2.5	12
111	A spleen stiffness measurement-based model for recognition of high risk varices: Baveno VI criteria and beyond. <i>Journal of Hepatology</i> , 2018, 68, S75-S76.	3.7	2
112	Prognostic Significance of Controlled Attenuation Parameter in Patients With Compensated Advanced Chronic Liver Disease. <i>Hepatology Communications</i> , 2018, 2, 933-944.	4.3	21
113	Portal Hypertension and a Stiff Liver. <i>Cureus</i> , 2018, 10, e2768.	0.5	0
114	Reliability Criteria for Liver Stiffness Measurements with Real-Time 2D Shear Wave Elastography in Different Clinical Scenarios of Chronic Liver Disease. <i>Ultraschall in Der Medizin</i> , 2017, 38, 648-654.	1.5	42
115	Prevention and treatment of variceal haemorrhage in 2017. <i>Liver International</i> , 2017, 37, 104-115.	3.9	57
116	Reply. <i>Hepatology</i> , 2017, 65, 2131-2132.	7.3	0
117	Non-invasive evaluation of portal hypertension using ultrasound elastography. <i>Journal of Hepatology</i> , 2017, 67, 399-411.	3.7	211
118	EFSUMB Guidelines and Recommendations on the Clinical Use of Liver Ultrasound Elastography, Update 2017 (Long Version). <i>Ultraschall in Der Medizin</i> , 2017, 38, e16-e47.	1.5	659
119	EFSUMB Guidelines and Recommendations on the Clinical Use of Liver Ultrasound Elastography, Update 2017 (Short Version). <i>Ultraschall in Der Medizin</i> , 2017, 38, 377-394.	1.5	93
120	Portal vein thrombosis: The role of imaging in the clinical setting. <i>Digestive and Liver Disease</i> , 2017, 49, 113-120.	0.9	63
121	Portosystemic shunts in cirrhosis are associated to more complications and deteriorated quality of life. An international cohort study. <i>Digestive and Liver Disease</i> , 2017, 49, e65.	0.9	0
122	Reply. <i>Hepatology</i> , 2017, 66, 302-303.	7.3	2
123	Effects of an intensive lifestyle intervention program on portal hypertension in patients with cirrhosis and obesity: The SportDiet study. <i>Hepatology</i> , 2017, 65, 1293-1305.	7.3	225
124	Vascular diseases of the liver. Clinical Guidelines from the Catalan Society of Digestology and the Spanish Association for the Study of the Liver. <i>GastroenterologÅa Y HepatologÅa (English Edition)</i> , 2017, 40, 538-580.	0.1	10
125	Controlled attenuation parameter as an additional tool for the non-invasive prediction of first clinical decompensation in compensated advanced chronic liver disease. <i>Journal of Hepatology</i> , 2017, 66, S91-S92.	3.7	1
126	Expanding the Baveno VI criteria for the screening of varices in patients with compensated advanced chronic liver disease. <i>Hepatology</i> , 2017, 66, 1980-1988.	7.3	223

#	ARTICLE	IF	CITATIONS
127	Enfermedades vasculares del h�gado. Gu�as Cl�nicas de la Sociedad Catalana de Digestolog�a y de la Asociaci�n Espa�ola para el Estudio del H�gado. Gastroenterolog�a Y Hepatolog�a, 2017, 40, 538-580.	0.5	20
128	Portosystemic shunts in cirrhosis are associated to more complications and deteriorated quality of life: an international cohort study. Journal of Hepatology, 2017, 66, S386.	3.7	0
129	Portal hypertensive bleeding in cirrhosis: Risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases. Hepatology, 2017, 65, 310-335.	7.3	1,520
130	Diagnostic hepatic haemodynamic techniques: safety and radiation exposure. Liver International, 2017, 37, 148-154.	3.9	10
131	Diagnosis of cirrhosis and portal hypertension: imaging, non-invasive markers of fibrosis and liver biopsy. Gastroenterology Report, 2017, 5, 79-89.	1.3	117
132	Advances and challenges in cirrhosis and portal hypertension. BMC Medicine, 2017, 15, 200.	5.5	64
133	Metabolomics as a diagnostic tool for idiopathic non�cirrhotic portal hypertension. Liver International, 2016, 36, 1051-1058.	3.9	15
134	Physical activity and liver diseases. Hepatology, 2016, 63, 1026-1040.	7.3	142
135	Emerging therapies for portal hypertension in cirrhosis. Expert Opinion on Emerging Drugs, 2016, 21, 167-181.	2.4	20
136	Noninvasive tools and risk of clinically significant portal hypertension and varices in compensated cirrhosis: The "Anticipate" study. Hepatology, 2016, 64, 2173-2184.	7.3	251
137	Portal Vein Thrombosis in Patients with Cirrhosis. Incidence and Factors Associated with Its Development. Journal of Hepatology, 2016, 64, S260.	3.7	2
138	Editorial: increased cardiac output in cirrhosis "non�invasive assessment of regional blood flow by magnetic resonance angiography. Alimentary Pharmacology and Therapeutics, 2016, 43, 1340-1342.	3.7	3
139	AISF position paper on liver transplantation and pregnancy. Digestive and Liver Disease, 2016, 48, 860-868.	0.9	20
140	Addition of Simvastatin to Standard Therapy for the Prevention of Variceal Rebleeding Does Not Reduce Rebleeding but Increases Survival in Patients With Cirrhosis. Gastroenterology, 2016, 150, 1160-1170.e3.	1.3	232
141	Sequential Functions of CPEB1 and CPEB4 Regulate Pathologic Expression of Vascular Endothelial Growth Factor and Angiogenesis in Chronic Liver Disease. Gastroenterology, 2016, 150, 982-997.e30.	1.3	73
142	Results of the Questionnaire. , 2016, , 31-37.		0
143	O074 : A metabolomic study of serum from patients with cirrhosis identifies 2 metabolites that accurately predict the acute HVPG response to �-blocker therapy. Journal of Hepatology, 2015, 62, S227-S228.	3.7	1
144	Prognosis of acute variceal bleeding: Is being on beta�blockers an aggravating factor? A short�term survival analysis. Hepatology, 2015, 62, 1840-1846.	7.3	11

#	ARTICLE	IF	CITATIONS
145	Reply. <i>Hepatology</i> , 2015, 62, 978-979.	7.3	0
146	Value of Transient Elastography Measured With Fibroscan in Predicting the Outcome of Hepatic Resection for Hepatocellular Carcinoma. <i>Annals of Surgery</i> , 2015, 261, e105.	4.2	8
147	Assessment of Hepatic Vascular Network Connectivity with Automated Graph Analysis of Dynamic Contrast-enhanced US to Evaluate Portal Hypertension in Patients with Cirrhosis: A Pilot Study. <i>Radiology</i> , 2015, 277, 268-276.	7.3	26
148	Antiangiogenic and antifibrogenic activity of pigment epithelium-derived factor (PEDF) in bile duct-ligated portal hypertensive rats. <i>Gut</i> , 2015, 64, 657-666.	12.1	48
149	O017A : Non-invasive tools and risk of varices and clinically significant portal hypertension in compensated cirrhosis: the "anticipate" study. <i>Journal of Hepatology</i> , 2015, 62, S198-S199.	3.7	3
150	Serum tests, liver stiffness and artificial neural networks for diagnosing cirrhosis and portal hypertension. <i>Digestive and Liver Disease</i> , 2015, 47, 411-416.	0.9	40
151	Diagnostic accuracy of liver and spleen stiffness measurement for portal hypertension using bidimensional shear wave elastography. <i>Digestive and Liver Disease</i> , 2015, 47, e18.	0.9	0
152	Reply to "Points to be considered when using transient elastography for diagnosis of portal hypertension according to the Baveno VI consensus". <i>Journal of Hepatology</i> , 2015, 63, 1049-1050.	3.7	5
153	Effects of Sapropterin on Portal and Systemic Hemodynamics in Patients With Cirrhosis and Portal Hypertension: A Bicentric Double-Blind Placebo-Controlled Study. <i>American Journal of Gastroenterology</i> , 2015, 110, 985-992.	0.4	25
154	Clinical Evaluation and Prognosis. <i>Digestive Diseases</i> , 2015, 33, 515-523.	1.9	10
155	A prospective observational study on tolerance and satisfaction to hepatic haemodynamic procedures. <i>Liver International</i> , 2015, 35, 695-703.	3.9	18
156	Real-time shear-wave elastography: Applicability, reliability and accuracy for clinically significant portal hypertension. <i>Journal of Hepatology</i> , 2015, 62, 1068-1075.	3.7	183
157	Portal hypertension and the outcome of surgery for hepatocellular carcinoma in compensated cirrhosis: A systematic review and meta-analysis. <i>Hepatology</i> , 2015, 61, 526-536.	7.3	286
158	Non-Invasive Assessment of Non-Alcoholic Fatty Liver Disease: Ultrasound and Transient Elastography. <i>Reviews on Recent Clinical Trials</i> , 2015, 9, 170-177.	0.8	12
159	Impact of deep sedation on the accuracy of hepatic and portal venous pressure measurements in patients with cirrhosis. <i>Liver International</i> , 2014, 34, 16-25.	3.9	64
160	Regarding "liver stiffness is influenced by a standardized meal in patients with chronic hepatitis C virus at different stages of fibrotic evolution". <i>Hepatology</i> , 2014, 59, 350-351.	7.3	4
161	Use of noninvasive markers of portal hypertension and timing of screening endoscopy for gastroesophageal varices in patients with chronic liver disease. <i>Hepatology</i> , 2014, 59, 729-731.	7.3	28
162	A MELD-Based Model to Determine Risk of Mortality Among Patients With Acute Variceal Bleeding. <i>Gastroenterology</i> , 2014, 146, 412-419.e3.	1.3	285

#	ARTICLE	IF	CITATIONS
163	Getting closer to a point-of-care diagnostic assessment in patients with chronic liver disease: Controlled attenuation parameter for steatosis. <i>Journal of Hepatology</i> , 2014, 60, 910-912.	3.7	35
164	Disruption of negative feedback loop between vasohibin-1 and vascular endothelial growth factor decreases portal pressure, angiogenesis, and fibrosis in cirrhotic rats. <i>Hepatology</i> , 2014, 60, 633-647.	7.3	44
165	Pharmacologic Management of Portal Hypertension. <i>Clinics in Liver Disease</i> , 2014, 18, 303-317.	2.1	37
166	Idiopathic portal hypertension: Natural history and long-term outcome. <i>Hepatology</i> , 2014, 59, 2276-2285.	7.3	132
167	Imaging in clinical decision-making for portal vein thrombosis. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2014, 11, 308-316.	17.8	64
168	P460 A METABOLOMIC PROFILE INCLUDING 5 LIPIDIC METABOLITES CORRELATES WITH DIAGNOSIS OF IDIOPATHIC PORTAL HYPERTENSION. <i>Journal of Hepatology</i> , 2014, 60, S222.	3.7	0
169	P518 HEPATIC VENOUS PRESSURE GRADIENT, ASA CLASS AND TYPE OF SURGERY ARE PROGNOSTIC FACTORS OF EXTRA-HEPATIC SURGERY IN PATIENTS WITH CIRRHOSIS: A MULTI-CENTER PROSPECTIVE OBSERVATIONAL STUDY. <i>Journal of Hepatology</i> , 2014, 60, S242.	3.7	1
170	Use of Vasoactive Drugs for Acute Variceal Bleeding. , 2014, , 135-145.		0
171	621 IMPROVING RISK PREDICTION IN ACUTE VARICEAL BLEEDING WITH OBJECTIVE VARIABLES: THE ROLE OF MELD. <i>Journal of Hepatology</i> , 2013, 58, S254.	3.7	1
172	Update on ultrasound imaging of liver fibrosis. <i>Journal of Hepatology</i> , 2013, 59, 180-182.	3.7	87
173	Impact of obesity and insulin-resistance on cirrhosis and portal hypertension. <i>Gastroenterology</i> , 2013, 144, 1153-1154.	0.5	23
174	193 RELIABILITY OF THE ESTIMATION OF HEPATIC BLOOD FLOW (HBF) BY DOPPLER ULTRASOUND IN PATIENTS WITH CIRRHOTIC PORTAL HYPERTENSION: COMPARISON WITH HBF BY INDOCYANINE GREEN. <i>Journal of Hepatology</i> , 2013, 58, S85.	3.7	0
175	Reply. <i>Gastroenterology</i> , 2013, 144, 1153-1154.	1.3	0
176	Elastography, Spleen Size, and Platelet Count Identify Portal Hypertension in Patients With Compensated Cirrhosis. <i>Gastroenterology</i> , 2013, 144, 102-111.e1.	1.3	437
177	Metabolomics Discloses Potential Biomarkers for the Noninvasive Diagnosis of Idiopathic Portal Hypertension. <i>American Journal of Gastroenterology</i> , 2013, 108, 926-932.	0.4	28
178	Assessing portal hypertension in liver diseases. <i>Expert Review of Gastroenterology and Hepatology</i> , 2013, 7, 141-155.	3.0	241
179	Reliability of the estimation of total hepatic blood flow by Doppler ultrasound in patients with cirrhotic portal hypertension. <i>Journal of Hepatology</i> , 2013, 59, 717-722.	3.7	17
180	If portal hypertension predicts outcome in cirrhosis, why should this not be the case after surgical resection?. <i>Liver International</i> , 2013, 33, 1454-1456.	3.9	5

#	ARTICLE	IF	CITATIONS
181	Hemodynamic response to propranolol in patients with recurrent hepatitis C virus-related cirrhosis after liver transplantation: A case-control study. <i>Liver Transplantation</i> , 2013, 19, 450-456.	2.4	8
182	Cardiovascular Risk Factors and Systemic Endothelial Function in Patients With Cirrhosis. <i>American Journal of Gastroenterology</i> , 2013, 108, 75-82.	0.4	27
183	Spleen stiffness: Toward a noninvasive portal sphygmomanometer?. <i>Hepatology</i> , 2013, 57, 1278-1280.	7.3	22
184	Effect of Meal Ingestion on Liver Stiffness in Patients with Cirrhosis and Portal Hypertension. <i>PLoS ONE</i> , 2013, 8, e58742.	2.5	110
185	Management of small hepatocellular carcinoma in cirrhosis: Focus on portal hypertension. <i>World Journal of Gastroenterology</i> , 2013, 19, 1193.	3.3	34
186	Insulin resistance in patients with cirrhosis and portal hypertension. <i>American Journal of Physiology - Renal Physiology</i> , 2012, 302, G1458-G1465.	3.4	23
187	Transjugular intrahepatic portosystemic shunt placement for refractory ascites: a single-centre experience. <i>Scandinavian Journal of Gastroenterology</i> , 2012, 47, 1494-1500.	1.5	19
188	Ultraschall bei Pfortaderhochdruck " Teil 2 " und EFSUMB-Empfehlungen zur Durchfhrung und Dokumentation von Ultraschalluntersuchungen bei Pfortaderhochdruck. <i>Ultraschall in Der Medizin</i> , 2012, 33, 8-32.	1.5	84
189	Postprandial effects of dark chocolate on portal hypertension in patients with cirrhosis: results of a phase 2, double-blind, randomized controlled trial. <i>American Journal of Clinical Nutrition</i> , 2012, 96, 584-590.	4.7	50
190	Assessment of portal hypertension by transient elastography in patients with compensated cirrhosis and potentially resectable liver tumors. <i>Journal of Hepatology</i> , 2012, 56, 103-108.	3.7	142
191	Portal hypertension and liver cirrhosis in rats: effect of the β_3 -adrenoceptor agonist SR58611A. <i>British Journal of Pharmacology</i> , 2012, 167, 1137-1147.	5.4	17
192	Role of hepatic vein catheterisation and transient elastography in the diagnosis of idiopathic portal hypertension. <i>Digestive and Liver Disease</i> , 2012, 44, 855-860.	0.9	113
193	Diagnosing and monitoring cirrhosis: Liver biopsy, hepatic venous pressure gradient and elastography. <i>Gastroenterolog Y Hepatolog</i> , 2012, 35, 488-495.	0.5	37
194	Patients Whose First Episode of Bleeding Occurs While Taking a β_2 -Blocker Have High Long-term Risks of Rebleeding and Death. <i>Clinical Gastroenterology and Hepatology</i> , 2012, 10, 670-676.	4.4	26
195	Transient elastography and prognosis of cirrhosis. <i>Hepatology</i> , 2012, 55, 1629-1631.	7.3	8
196	F-4 Hemodynamic response to beta-blockers for portal hypertension: A single center experience. <i>Digestive and Liver Disease</i> , 2011, 43, S93.	0.9	0
197	Evaluation of regional hepatic perfusion (RHP) by contrast-enhanced ultrasound in patients with cirrhosis. <i>Journal of Hepatology</i> , 2011, 55, 307-314.	3.7	43
198	590 ASSESSMENT OF SYSTEMIC ENDOTHELIAL FUNCTION IN PATIENTS WITH CIRRHOSIS: COMPARISON BETWEEN PERIPHERAL ARTERIAL TONOMETRY (PAT) AND BRACHIAL ARTERY VASODILATATION BY ULTRASOUND (BAUS). <i>Journal of Hepatology</i> , 2011, 54, S240.	3.7	0

#	ARTICLE	IF	CITATIONS
199	Routine blood tests? Helping you live(r) longer!. Lancet, The, 2011, 378, 2048.	13.7	0
200	Non-Invasive Diagnostic and Prognostic Evaluation of Liver Cirrhosis and Portal Hypertension. Disease Markers, 2011, 31, 129-138.	1.3	76
201	Prognostic value of a single HVPG measurement and Doppler-ultrasound evaluation in patients with cirrhosis and portal hypertension. Journal of Gastroenterology, 2011, 46, 687-695.	5.1	70
202	Obesity is an independent risk factor for clinical decompensation in patients with cirrhosis. Hepatology, 2011, 54, 555-561.	7.3	240
203	Ultraschall bei Pfortaderhochdruck – Teil 1. Ultraschall in Der Medizin, 2011, 32, 548-571.	1.5	66
204	Non-invasive diagnostic and prognostic evaluation of liver cirrhosis and portal hypertension. Disease Markers, 2011, 31, 129-38.	1.3	36
205	Liver hemangioma and vascular liver diseases in patients with systemic lupus erythematosus. World Journal of Gastroenterology, 2011, 17, 4503.	3.3	23
206	Chronic endurance exercise training prevents aging-related cognitive decline in healthy older adults: a randomized controlled trial. International Journal of Geriatric Psychiatry, 2010, 25, 1055-1064.	2.7	113
207	Circulating and hepatic endocannabinoids and endocannabinoid-related molecules in patients with cirrhosis. Liver International, 2010, 30, 816-825.	3.9	69
208	Right atrial pressure is not adequate to calculate portal pressure gradient in cirrhosis: A clinical-hemodynamic correlation study. Hepatology, 2010, 51, 2108-2116.	7.3	74
209	NCX-1000, a Nitric Oxide-Releasing Derivative of UDCA, Does Not Decrease Portal Pressure in Patients With Cirrhosis: Results of a Randomized, Double-Blind, Dose-Escalating Study. American Journal of Gastroenterology, 2010, 105, 1094-1101.	0.4	40
210	A Specialized, Nurse-Run Titration Clinic: A Feasible Option for Optimizing β -Blockade in Non-Clinical Trial Patients. American Journal of Gastroenterology, 2010, 105, 1917-1921.	0.4	13
211	Refractory Acute Variceal Bleeding: What to Do Next?. Clinics in Liver Disease, 2010, 14, 297-305.	2.1	30
212	Clinical significance of worsening portal hypertension during long-term medical treatment in patients with cirrhosis who had been classified as early good-responders on haemodynamic criteria. Journal of Hepatology, 2010, 52, 45-53.	3.7	26
213	Ultrasonographic evaluation of liver surface and transient elastography in clinically doubtful cirrhosis. Journal of Hepatology, 2010, 52, 846-853.	3.7	114
214	Renin-angiotensin-aldosterone inhibitors in the reduction of portal pressure: A systematic review and meta-analysis. Journal of Hepatology, 2010, 53, 273-282.	3.7	112
215	198 RENIN-ANGIOTENSIN-ALDOSTERONE INHIBITORS FOR THE REDUCTION OF PORTAL PRESSURE: A META-ANALYSIS AND SYSTEMATIC REVIEW. Journal of Hepatology, 2010, 52, S85-S86.	3.7	0
216	422 IDIOPATHIC PORTAL HYPERTENSION: IMPACT OF HEPATIC VEIN CATHETERIZATION AND TRANSIENT ELASTOGRAPHY ON ITS DIAGNOSIS. Journal of Hepatology, 2010, 52, S172.	3.7	2

#	ARTICLE	IF	CITATIONS
217	508 INSULIN RESISTANCE AND DIABETES DO NOT INFLUENCE HEPATIC AND SYSTEMIC HEMODYNAMICS OR THE HVPG RESPONSE TO PROPRANOLOL IN PATIENTS WITH CIRRHOSIS. <i>Journal of Hepatology</i> , 2010, 52, S205.	3.7	0
218	Age Dependency of Regional Impedance Indices Regardless of Clinical Stage in Patients with Cirrhosis of the Liver. <i>Ultraschall in Der Medizin</i> , 2009, 30, 277-285.	1.5	4
219	Doppler Ultrasound Findings in the Hepatic Artery Shortly After Liver Transplantation. <i>American Journal of Roentgenology</i> , 2009, 193, 128-135.	2.2	82
220	Apelin signaling modulates splanchnic angiogenesis and portosystemic collateral vessel formation in rats with portal hypertension. <i>Journal of Hepatology</i> , 2009, 50, 296-305.	3.7	72
221	Prognostic value of acute hemodynamic response to i.v. propranolol in patients with cirrhosis and portal hypertension. <i>Journal of Hepatology</i> , 2009, 51, 279-287.	3.7	116
222	â€œTorsade de pointesâ€•during amiodarone infusion in a cirrhotic woman with a prolonged QT interval. <i>Digestive and Liver Disease</i> , 2009, 41, 535-538.	0.9	10
223	Factors predicting mortality after TIPS for refractory ascites: A single center experience. <i>Digestive and Liver Disease</i> , 2009, 41, A42.	0.9	1
224	The clinical use of HVPG measurements in chronic liver disease. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2009, 6, 573-582.	17.8	576
225	178 COMPARISON OF ULTRASONOGRAPHIC EVALUATION OF LIVER SURFACE AND TRANSIENT ELASTOGRAPHY IN THE DIAGNOSIS OF CIRRHOSIS AND PORTAL HYPERTENSION. <i>Journal of Hepatology</i> , 2009, 50, S74-S75.	3.7	0
226	739 CIRCULATING AND HEPATIC ENDOCANNABINOIDS AND ENDOCANNABINOID-RELATED MOLECULES IN PATIENTS WITH LIVER CIRRHOSIS. <i>Journal of Hepatology</i> , 2009, 50, S271-S272.	3.7	1
227	748 EFFECT OF B3-ADRENOCEPTOR MODULATION ON PORTAL PRESSURE IN RATS WITH COMPENSATED CIRRHOSIS. <i>Journal of Hepatology</i> , 2009, 50, S275.	3.7	0
228	Pathophysiology of portal hypertension and variceal bleeding. , 2009, , 137-148.		0
229	The management of portal hypertension: Rational basis, available treatments and future options. <i>Journal of Hepatology</i> , 2008, 48, S68-S92.	3.7	248
230	New abdominal collaterals at ultrasound: A clue of progression of portal hypertension. <i>Digestive and Liver Disease</i> , 2008, 40, 62-67.	0.9	33
231	Prevention of recurrent variceal bleeding. <i>Digestive and Liver Disease</i> , 2008, 40, 337-342.	0.9	10
232	Effect of chronic β_2 -blockade on QT interval in patients with liver cirrhosis. <i>Journal of Hepatology</i> , 2008, 48, 415-421.	3.7	83
233	Spleen Enlargement on Follow-Up Evaluation: A Noninvasive Predictor of Complications of Portal Hypertension in Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2008, 6, 1129-1134.	4.4	58
234	Noninvasive Prediction of Clinically Significant Portal Hypertension and Esophageal Varices in Patients With Compensated Liver Cirrhosis. <i>American Journal of Gastroenterology</i> , 2008, 103, 1159-1167.	0.4	131

#	ARTICLE	IF	CITATIONS
235	Portal Hypertension and Gastrointestinal Bleeding. <i>Seminars in Liver Disease</i> , 2008, 28, 003-025.	3.6	114
236	Sixty years is not an age limit in patients submitted to liver transplantation. <i>Digestive and Liver Disease</i> , 2007, 39, A40.	0.9	0
237	237 Long-term beta-blockade shortens QT interval prolongation in patients with liver cirrhosis. <i>Journal of Hepatology</i> , 2006, 44, S95.	3.7	0
238	673 Prevalence and factors associated with fatty liver in a geriatric population: Results from the pianoro study. <i>Journal of Hepatology</i> , 2006, 44, S248.	3.7	0
239	Octreotide in the outpatient therapy of cirrhotic chylous ascites: A case report. <i>Digestive and Liver Disease</i> , 2006, 38, 138-42.	0.9	22
240	Primary prophylaxis with nadolol in cirrhotic patients: Doppler patterns of splanchnic hemodynamics in good and poor responders. <i>Journal of Hepatology</i> , 2006, 44, 310-316.	3.7	19
241	Isolated hepatic tuberculoma after orthotopic liver transplantation: a case report. <i>Internal and Emergency Medicine</i> , 2006, 1, 314-316.	2.0	6
242	Plasma total homocysteine and cardiovascular risk in patients submitted to liver transplantation. <i>Liver Transplantation</i> , 2006, 12, 105-111.	2.4	43
243	Measurement of Portal Pressure and Its Role in the Management of Chronic Liver Disease. <i>Seminars in Liver Disease</i> , 2006, 26, 348-362.	3.6	182
244	Renovascular Impedance Correlates with Portal Pressure in Patients with Liver Cirrhosis. <i>Radiology</i> , 2006, 240, 581-586.	7.3	42
245	Non-cardiac determinants of NT-proBNP levels in the elderly: Relevance of haematocrit and hepatic steatosis. <i>European Journal of Heart Failure</i> , 2006, 8, 468-476.	7.1	24
246	Peliosis hepatis as an early histological finding in idiopathic portal hypertension: A case report. <i>World Journal of Gastroenterology</i> , 2006, 12, 3612.	3.3	23
247	Reduced prevalence of ischemic events and abnormal supraortic flow patterns in patients with liver cirrhosis. <i>Liver International</i> , 2005, 25, 331-336.	3.9	49
248	Utility of Color Doppler Ultrasonography Predicting TIPS Dysfunction. <i>American Journal of Gastroenterology</i> , 2005, 100, 2696-2701.	0.4	49
249	Simvastatin enhances hepatic nitric oxide production and decreases the hepatic vascular tone in patients with cirrhosis. <i>Gastroenterology</i> , 2004, 126, 749-755.	1.3	258
250	Splanchnic haemodynamics in non-alcoholic fatty liver disease: effect of a dietary/pharmacological treatment. <i>Digestive and Liver Disease</i> , 2004, 36, 406-411.	0.9	40
251	205 Age-related changes of splanchnic hemodynamics in patients with liver cirrhosis. <i>Journal of Hepatology</i> , 2004, 40, 66.	3.7	0
252	Postprandial splanchnic haemodynamic changes in patients with liver cirrhosis and patent paraumbilical vein. <i>European Journal of Gastroenterology and Hepatology</i> , 2004, 16, 1339-1345.	1.6	6

#	ARTICLE	IF	CITATIONS
253	Low doses of isosorbide mononitrate attenuate the postprandial increase in portal pressure in patients with cirrhosis. <i>Hepatology</i> , 2003, 37, 378-384.	7.3	78
254	Splanchnic haemodynamics in patients with coeliac disease: effects of a gluten-free diet. <i>Digestive and Liver Disease</i> , 2003, 35, 262-268.	0.9	18
255	Simvastatin ameliorates the increased hepatic vascular tone in patients with cirrhosis. <i>Journal of Hepatology</i> , 2003, 38, 12.	3.7	3
256	New Tools for the Noninvasive Assessment of Cirrhosis. <i>Current Hepatology Reports</i> , 0, , .	0.9	2
257	Session 3: Prevention of the Formation of Varices (Pre-Primary Prophylaxis). , 0, , 103-151.		3
258	Exercise Interventions for Cirrhosis. <i>Current Treatment Options in Gastroenterology</i> , 0, , .	0.8	0